AUDUBON, Pa., March  23, 2026  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the

GMED

Globus Medical Announces Board Departure

Globus Medical Board Member Resignation May Impact Future Strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>AUDUBON, Pa., March  23, 2026  (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>John A. DeFord, a director at Globus Medical, has resigned and will not seek re-election. His departure may affect the company&#039;s strategic leadership, particularly following the recent merger with NuVasive.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>John A. DeFord resigns from Globus Medical&#039;s Board of Directors effective immediately.</li><li>DeFord will not seek re-election at the June 2026 Annual Meeting.</li><li>His contributions included involvement during the NuVasive merger and governance.</li><li>Globus Medical continues to position as a leader in musculoskeletal technology.</li><li>The company expresses gratitude for DeFord&#039;s insights and experience.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>NuVasive (NUVA)</strong>: GMED&#039;s merger with NuVasive may require careful integration oversight post-resignation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits within Corporate Developments as it involves a significant leadership change. Such transitions can influence strategic decision-making and operational priorities, affecting stakeholder confidence and financial performance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Resignation of a board member could signal changes in strategic direction.</li><li>Need for new board members might introduce fresh perspectives to management.</li><li>Focus on past contributions indicates potential shifts in corporate governance.</li><li>Market reaction can hinge on investor confidence in succession planning.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>John A. DeFord resigns effective immediately as of March 23, 2026.</li><li>He served during the merger with NuVasive and on the Nominating Committee.</li><li>Annual Meeting of Stockholders is scheduled for June 3, 2026.</li><li>Globus Medical specializes in musculoskeletal solutions technology.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors may consider holding GMED as leadership transitions could provide strategic opportunities in the medium term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>AUDUBON, Pa., March  23, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=aUtGycoAifYL61N3wyhYZeVdj31ezC_b2or7adJziANFLHiFuG6SE4g_y1smWFlXmYhoD1cMNOgPF7Cmo9VG8mvA-Vrxkm5mssS8bB3BpuE=" rel="nofollow" target="_blank">Globus Medical</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/GMED">GMED</a>), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026.</p>  <p>"We are grateful for John's many contributions, especially during the merger with NuVasive and his service on the Nominating and Governance Committee. While we will miss his insights and expertise, we wish him continued success in his future endeavors," said David C. Paul, Chairman of the Board.</p>  <p>"It has been a privilege and pleasure to serve on the Board of Globus alongside such a dedicated team while experiencing the Company's significant growth as a leader in musculoskeletal technology," said Dr. John DeFord.</p>  <p><strong>About Globus Medical, Inc.</strong><br></br>Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at <a href="https://www.globenewswire.com/Tracker?data=V-_o4Y6gPUf5lotrNJBQ1r7gTLtulIeOurkoqCiscw9V7diwEZdOwCI5sggKH3bt7bMsqnQFczFYTlE8MJ5Dj_5vUZ1In7y-_4SWBfBrjPA=" rel="nofollow" target="_blank">www.globusmedical.com</a>.</p>  <p><strong>Safe Harbor Statements</strong><br></br>All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"), including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in our subsequent filings with the SEC. These documents are available at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.</p>  <p><strong>Contact:</strong><br></br>Brian Kearns<br></br>Senior Vice President, Corporate Development and Investor Relations<br></br>Phone: (610) 930-1800<br></br>Email: <a href="mailto:investors@globusmedical.com">investors@globusmedical.com</a><br></br>www.globusmedical.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3NzE0MCM3NDk5ODM2IzIwMDg4MjQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MDQ2ZDQ0NmYtZjY5My00ODliLWI0MDMtY2UwMmVjNDJjODdiLTEwMjAzOTctMjAyNi0wMy0yMy1lbg==/tiny/Globus-Medical.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/46f81a86-b794-42b0-bf72-63447eb13f53"><img src="https://ml.globenewswire.com/media/46f81a86-b794-42b0-bf72-63447eb13f53/small/gmlogo-2024-rgb-high-png.png" border="0" width="150" height="118" alt="Primary Logo"></img></a></p>

John A. DeFord, a director at Globus Medical, has resigned and will not seek re-election. His departure may affect the company's strategic leadership, particularly following the recent merger with NuVasive.

Globus Medical Announces Board Departure

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News